Taysha Gene Therapies Inc

Important metrics include cash and short-term investments, total assets, current assets, total liabilities, current liabilities, long-term debt, shareholders' equity, retained earnings, inventory, receivables, working capital, current ratio, quick ratio, debt-to-equity ratio, and return on equity. Investors usually review these together rather than relying on one number.

Assets are resources the company owns or controls, such as cash, receivables, inventory, investments, and property. Liabilities are obligations the company owes, such as accounts payable, debt, leases, and taxes. Shareholders' equity is the residual value after liabilities are subtracted from assets.

Current assets and current liabilities are generally expected to be converted, used, paid, or settled within one year or one operating cycle. Non-current assets and non-current liabilities are longer-term items, such as property, long-term investments, deferred tax assets, long-term debt, and lease obligations.

In its most recent quarterly, Taysha Gene Therapies Inc had 276.58M in cash and cash equivalents.

Taysha Gene Therapies Inc reported 96.38M in total liabilities as of the latest reported quarter, including 26.55M in current liabilities and 69.83M in non-current liabilities.

As of the latest reported quarter, Taysha Gene Therapies Inc's total assets were 343.32M, consisting of 324.65M in current assets and 18.67M in non-current assets.

Taysha Gene Therapies Inc reported 246.94M in total shareholders' equity as of the latest reported quarter.